Tirepatid beats Semaglutid: Revolution started in losing weight!

Tirepatid beats Semaglutid: Revolution started in losing weight!

Österreich - A current study shows that the Tirzidatide drug is more effective when losing weight than Semaglutid. This was found in the Surmount-5 phase 3B study, which was carried out by the manufacturer Lilly. 751 adults with obesity or overweight without type 2 diabetes took part in the study and received tirepatide in doses of 10 mg or 15 mg or semaglutid in doses of 1.7 mg or 2.4 mg as injection for over 72 weeks. The average weight loss was 20.2 % of the body weight in Tirzidatid, while participants lost only 13.7 %, reports t-online.de .

In addition to the study, the waist size among the Tirzida participants was significantly reduced by approx. 18.4 cm, compared to 13 cm in the Semaglutid participants. A larger abdominal range is a well-known risk factor for cardiovascular diseases, type 2 diabetes and the metabolic syndrome. Both medication also improved blood pressure and blood sugar levels; The systolic blood pressure dropped by 10.2 mm Hg in Tirzidatide, while at Semaglutid it dropped by 7.7 mm HG. The therapy aborts due to side effects were somewhat more common in the Semaglutide group, whereby the side effects in both groups were predominantly easy to moderate, reports universimed.com .

therapeutic management and new substances

The therapeutic management of obesity is based on four pillars: nutritional therapy, movement therapy, drug therapy and bariatric therapy, especially in the case of severe forms of obesity. In the coming years it will be expected that new substances, including duals and triple agonists, are expected to expand the therapy approach. These drugs could delay bariatric operations in the future, according to the experts. The use of GLP-1 receptor agonists for weight reduction has already proven to be very effective in clinical studies, as the medication Liraglutid and Semaglutid, who achieved significant weight reductions in the patient, explains Medicine.studio .

Medicines such as Orlistat, Naltrexon/Bupropion, Liraglutid and Semaglutid are currently approved for obesity treatment. The classic drug Liraglutid has shown an average weight loss of 7 % over 160 weeks, and Semaglutid achieved weight reduction in studies of up to 16 % in 68 weeks. Tirepatid is the first dual GLP-1/GIP agonist, with positive results in the Surmount 1 study, in which a weight loss of 20.9 % was achieved.

Bariatric surgery and their meaning

Bariatric surgery remains an invasive but effective option for weight loss. Indications are a BMI of 40 kg/m² or 35 kg/m² in conjunction with comorbidities. However, an analysis shows that a third of the patients after Sleve gastrectomy needs a conversion to another procedure. A lifelong postoperative aftercare is required to avoid deficits and complications. The challenges in aftercare include possible relocations and eating disorders that also require attention and professional help.